Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD

Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.

Read the full article here

Related Articles

LISTEN TO THE EXPERTS

Sponsored by Novartis US Medical Affairs Elevated lipoprotein(a) (Lp[a]) represents the most common type of genetic dyslipidemia. 1 Elevated Lp(a) levels occurring in 20% of…